Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care

Trial Profile

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Brodalumab (Primary) ; Interleukin-17 inhibitors
  • Indications Psoriasis
  • Focus Adverse reactions
  • Sponsors Ortho Dermatologics; Valeant Pharmaceuticals International
  • Most Recent Events

    • 21 Aug 2017 New trial record
    • 27 Jul 2017 According to Valeant Pharmaceuticals International media release, Valeant Pharmaceuticals International renamed its dermatolgy unit as Ortho Dermatologics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top